Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Dumas

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Revue Des Maladies Respiratoires|March 22, 2015
[Genetic and environmental factors of asthma and allergy: Results of the EGEA study]E Bouzigon, R Nadif, N Le Moual, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.
The Journal of Infectious Diseases|December 12, 2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageAndrew H Talal, Emily O Dumas, Barbara Bauer, et al.
Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
Revue Des Maladies Respiratoires|March 22, 2015
[Genetic and environmental factors of asthma and allergy: Results of the EGEA study]E Bouzigon, R Nadif, N Le Moual, et al.
Journal of Medicinal Chemistry|January 18, 2018
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral BioavailabilityJohn T Randolph, A Chris Krueger, Pamela L Donner, et al.
Pageof 4